Citadel Advisors’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $81.5K | Buy |
+13,251
| New | +$79.4K | ﹤0.01% | 12838 |
|
|
2026
Q1 | – | Sell |
-4,299
| Closed | -$28.8K | – | 13484 |
|
|
2025
Q4 | $28.8K | Buy |
+4,299
| New | +$25.5K | ﹤0.01% | 12235 |
|
|
2025
Q2 | – | Sell |
-32,996
| Closed | -$138K | – | 13523 |
|
|
2025
Q1 | $187K | Buy |
32,996
+26,124
| +380% | +$334K | ﹤0.01% | 10548 |
|
|
2024
Q4 | $145K | Sell |
6,872
-4,727
| -41% | -$109K | ﹤0.01% | 10939 |
|
|
2024
Q3 | $312K | Sell |
11,599
-938
| -7% | -$27.6K | ﹤0.01% | 9254 |
|
|
2024
Q2 | $357K | Buy |
12,537
+10,638
| +560% | +$373K | ﹤0.01% | 8773 |
|
|
2024
Q1 | $80.5K | Buy |
+1,899
| New | +$85.4K | ﹤0.01% | 11642 |
|
|
2023
Q4 | – | Sell |
-189
| Closed | -$8.13K | – | 14683 |
|
|
2023
Q3 | $8.13K | Sell |
189
-188
| -50% | -$8.68K | ﹤0.01% | 13216 |
|
|
2023
Q2 | $20.7K | Sell |
377
-2,686
| -88% | -$147K | ﹤0.01% | 12698 |
|
|
2023
Q1 | $129K | Sell |
3,063
-1,144
| -27% | -$33.9K | ﹤0.01% | 10881 |
|
|
2022
Q4 | $117K | Buy |
4,207
+2,683
| +176% | +$66.1K | ﹤0.01% | 11007 |
|
|
2022
Q3 | $39K | Sell |
1,524
-13,370
| -90% | -$442K | ﹤0.01% | 11770 |
|
|
2022
Q2 | $537K | Buy |
14,894
+12,884
| +641% | +$581K | ﹤0.01% | 8479 |
|
|
2022
Q1 | $125K | Buy |
+2,010
| New | +$119K | ﹤0.01% | 12045 |
|
|
2021
Q4 | – | Sell |
-1,265
| Closed | -$88K | – | 14192 |
|
|
2021
Q3 | $88K | Buy |
+1,265
| New | +$101K | ﹤0.01% | 12992 |
|
|
2021
Q2 | – | Sell |
-1,303
| Closed | -$71K | – | 13972 |
|
|
2021
Q1 | $71K | Buy |
+1,303
| New | +$63.4K | ﹤0.01% | 12722 |
|
|
2020
Q3 | – | Sell |
-4,488
| Closed | -$139K | – | 10320 |
|
|
2020
Q2 | $139K | Buy |
+4,488
| New | +$121K | ﹤0.01% | 8794 |
|
|
2019
Q3 | – | Sell |
-5,867
| Closed | -$118K | – | 9403 |
|
|
2019
Q2 | $118K | Buy |
+5,867
| New | +$172K | ﹤0.01% | 8476 |
|
|
2018
Q4 | – | Sell |
-5,983
| Closed | -$314K | – | 9378 |
|
|
2018
Q3 | $314K | Buy |
+5,983
| New | +$336K | ﹤0.01% | 7485 |
|
|
2018
Q2 | – | Sell |
-1,281
| Closed | -$64K | – | 9002 |
|
|
2018
Q1 | $64K | Buy |
+1,281
| New | +$57.4K | ﹤0.01% | 7852 |
|
|
2016
Q2 | – | Sell |
-2,668
| Closed | -$81K | – | 7029 |
|
|
2016
Q1 | $81K | Buy |
+2,668
| New | +$75.6K | ﹤0.01% | 6106 |
|
|
2015
Q4 | – | Sell |
-1,505
| Closed | -$57K | – | 8891 |
|
|
2015
Q3 | $57K | Sell |
1,505
-111
| -7% | -$5.16K | ﹤0.01% | 7483 |
|
|
2015
Q2 | $93K | Buy |
+1,616
| New | +$92K | ﹤0.01% | 7145 |
|
|
2014
Q3 | – | Sell |
-10,586
| Closed | -$482K | – | 8222 |
|
|
2014
Q2 | $482K | Buy |
10,586
+9,181
| +653% | +$386K | ﹤0.01% | 4448 |
|
|
2014
Q1 | $67K | Buy |
1,405
+960
| +216% | +$43.7K | ﹤0.01% | 6525 |
|
|
2013
Q4 | $21K | Sell |
445
-5,306
| -92% | -$232K | ﹤0.01% | 6424 |
|
|
2013
Q3 | $229K | Buy |
5,751
+666
| +13% | +$26.2K | ﹤0.01% | 4636 |
|
|
2013
Q2 | $183K | Buy |
+5,085
| New | +$195K | ﹤0.01% | 4743 |
|
Other funds holding HBIO
WCM
MIM
NCNMGF
CCM
Citadel Advisors's HBIO Position: Q2 2026 in Review
Citadel Advisors opened a new position in Harvard Bioscience (HBIO) in Q2 2026: 13,251 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #12838 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HBIO as recently as Q4 2025.
Citadel Advisors first reported a position in HBIO in Q2 2013 and has held it in 28 quarters since. The position peaked at $537K in Q2 2022. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.
- Citadel Advisors held 13,251 shares of Harvard Bioscience worth $81.5K as of Q2 2026.
- Harvard Bioscience was a new Citadel Advisors position in Q2 2026.
- Harvard Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12838 holding.
- Citadel Advisors first reported a position in Harvard Bioscience in Q2 2013 and has held it in 28 quarters since.
- Citadel Advisors's Harvard Bioscience position peaked at $537K in Q2 2022.
- 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.